ASTRAZEN — Astrazeneca Pharma India Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Astrazeneca Pharma India, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	8,136	8,056	10,030	12,955	17,163
Cost of Revenue
Gross Profit	4,757	4,400	5,722	6,174	7,533
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	6,977	7,362	8,943	11,089	15,991
Operating Profit	1,159	694	1,086	1,866	1,172
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,271	830	1,341	2,195	1,564
Provision for Income Taxes
Net Income After Taxes	933	616	993	1,615	1,157
Net Income Before Extraordinary Items
Net Income	933	616	993	1,615	1,157
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	933	616	993	1,615	1,157
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	36.7	23.8	50.9	60.1	75
Dividends per Share